Comparison of the Effects of High Doses of Rosuvastatin Versus Atorvastatin on the Subpopulations of High-Density Lipoproteins
- 1 March 2007
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 99 (5) , 681-685
- https://doi.org/10.1016/j.amjcard.2006.09.117
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- High-Density Lipoprotein Subpopulation Profile and Coronary Heart Disease Prevalence in Male Participants of the Framingham Offspring StudyArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trialClinical Therapeutics, 2004
- Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiencyJournal of Lipid Research, 2004
- Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR * Trial)Published by Elsevier ,2003
- Change in α 1 HDL Concentration Predicts Progression in Coronary Artery StenosisArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patientsAtherosclerosis, 2002
- Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patientsJournal of Lipid Research, 2002
- Distribution of ApoA-I–Containing HDL Subpopulations in Patients With Coronary Heart DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-IThe American Journal of Cardiology, 1999
- Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.The American Journal of Cardiology, 1998